In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Endo launches unsolicited bid for Salix; withdraws offer

Executive Summary

Endo International PLC launched an unsolicited proposal to acquire gastrointestinal specialist Salix Pharmaceuticals Ltd. for a combination of 1.4607 Endo common shares and $45.00 in cash per Salix share, which would value the deal at $11bn ($171.81 for each Salix share).

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Withdrawn
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash
    • Payment Includes Stock

Related Companies